Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operati...( Year marked by strengthened leadersh...)

Year marked by strengthened leadership team and the initiation of Phase 3

program for cetrorelix in BPH

All amounts are in U.S. dollars

QUEBEC CITY, March 5 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), a global biopharmaceutical company focused on endocrinology and oncology, today reported financial and operating results for the fourth quarter and full year ended December 31, 2007.

David J. Mazzo, Ph.D., Aeterna Zentaris' President and Chief Executive Officer commented, "2007 was a challenging year; a year marked by important changes to both our corporate structure and business plan. The result has given our stakeholders a sharper image of our objectives and ongoing priorities. 2007 also involved a great deal of groundbreaking, marking for example, the first time our team launched an international Phase 3 program as is the case for cetrorelix in BPH. Another first was the opening of our offices in New Jersey as part of our strategy to gain more exposure with the pharmaceutical and financial communities in the United States. Furthermore, following the appointment of three new key executives during the year, we now have a team of the highest level in clinical research, regulatory affairs, business development, pharmaceutical discovery, development and commercialization - vital assets for the successful pre-launch activities for cetrorelix, as well as for the thrust of our entire pipeline.

Moving forward, we will continue to strive to expose the depth, breadth and potential of our robust pipeline and will diligently execute our business plan with the primary objective of creating value for our shareholders."

CONSOLIDATED RESULTS FOR THE FOUR
'/>"/>